

## CURRICULUM VITAE

**Dima Azzam Sabbah**  
**B. Pharm., M.S., Ph.D. Pharm. Sci.**

*Pharmacy Department, Faculty of Pharmacy*

*Al-Zaytoonah University of Jordan, Amman, Jordan*

*Phone: +9626-429-1511 (Ext 311) (Office)*

*+9627-974-949-27 (Cell phone)*

*Fax: +962-6-4291432*

*E-mail address: [dima.sabbah@zuj.edu.jo](mailto:dima.sabbah@zuj.edu.jo)*

*Homepage: <http://www.zuj.edu.jo/>*



### 1. Personal Data

Date of Birth: April 24<sup>th</sup> 1973

Nationality: Jordanian

### 2. Education

- Ph. D. (Pharmaceutical Sciences) 2012, University of Nebraska Medical Center, Omaha, Nebraska, USA
- M.Sc. (Pharmaceutical Sciences) 2003, The University of Jordan, Amman, Jordan
- B.Sc. (Pharmacy) 1996, The University of Jordan, Amman, Jordan

### 3. Ph.D. Dissertation

- *Computational Studies and Inhibitors Design of PI3K $\alpha$* , University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA

### 4. M.S. Thesis

*Synthesis of Some Novel Nitrofuran Derivatives of Potential Antimicrobial Activity.*  
The University of Jordan, Faculty of Pharmacy, Amman, Jordan.



## 5. Employment

### Academic Positions

- Professor, Pharmacy Department, Al-Zaytoonah University of Jordan, Amman, Jordan  
June 9<sup>th</sup> 2022- now
- Associate Professor, Pharmacy Department, Al-Zaytoonah University of Jordan, Amman, Jordan  
February 19<sup>th</sup> 2018- now
- Assistant Professor, Pharmacy Department, Al-Zaytoonah University of Jordan, Amman, Jordan  
October 31<sup>st</sup> 2012- February 18<sup>th</sup> 2018
- Ph. D. Student & Research Assistant, Pharmaceutical Sciences Department, University, University of Nebraska Medical Center, Omaha, NE  
August 17<sup>th</sup> 2007- September 30<sup>th</sup> 2012
- Instructor, Pharmacy Department, Al-Zaytoonah University of Jordan, Amman, Jordan  
January 1<sup>st</sup> 2004-August 15<sup>th</sup> 2007
- Teaching Assistant, , Pharmacy Department, Al-Zaytoonah University of Jordan, Amman, Jordan  
September 9<sup>th</sup> 1996- December 31<sup>st</sup> 2003

## 6. Research Interests

- Computational Chemistry
- Drug Design
- Medicinal Chemistry
- Organic Synthesis
- Drug Discovery

## 7. Membership in Scientific Societies and Associations

- Jordan Pharmaceutical Association
- American Chemical Society
- American Association of Pharmaceutical Scientists

## 8. Honors and Awards

- 2021 Al-Zaytoonah University of Jordan (ZUJ) Best Master Thesis Award received by M.Sc. *Reem Ahmad Isleem*.



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- 2020 Hamdi Mango Center for Scientific Research (HMCSR, The University of Jordan) (Samia Mango Distinguished Female Researcher Award).
- 2018 Al-Zaytoonah University of Jordan (ZUJ) Distinguished Researcher Award.
- 2017 Third Place in Postgraduate Poster Competition. ASU-Pharmacy Third Symposium "*Recent Trends in Postgraduate Research*" received by M.Sc. *Ameerah Saeed Ibrahim*.
- 2016 Second Place in Splendor of Pharmacists (SOP) Competition- Medicinal Chemistry (Structure-Based Drug Design) received by B. Sc. Students: *Hakam M. Al Aqabani & Ikhlas Altaweel*
- 2012 ADDF Young Investigator Scholarship
- 2011 COMP's Denver National Meeting Brochure Cover Image Contest
- 2011 Open Science Grid Summer School and TeraGrid '11 Conference Attendance
- 2009 AAPS Graduate Student Symposium Award in Drug Design & Discovery

#### 9. Fellowships and Scholarships

- 2010-2012: Bukey Fellowship
- 2007-2012: University of Nebraska Medical Center Graduate Studies Research Assistantship

#### 9. Teaching Experience

- ***Graduate Courses***

- Advanced Medicinal Chemistry & Drug Design
- Advanced Organic Chemistry
- Advanced Instrumental Analysis
- Research Methodology

- ***Undergraduate Courses***

- Medicinal Chemistry (I/II/III)
- Drug Design
- Pharmaceutical Organic Chemistry II



- Pharmaceutical Analytical Chemistry
- Pharmaceutical Organic Chemistry Lab
- Medicinal Chemistry Lab

## 10. Supervision of Graduate Research

### A. Internal

1. M. Sc. Student: *Sundos Fouad Aliyeh*, Development of a Polymeric Nanoparticle Formulation for Phosphatidylinositol 3-Kinase Alpha (PI3K $\alpha$ ) Inhibitors as a Potential Anticancer Nanomedicine, 2021-2022.
2. M. Sc. Student: *Qutaiba Salah Jasem*, Design, Synthesis, and Biological Evaluation of *N'*-(Diphenylmethylene) Benzohydrazide Derivatives as PI3K $\alpha$  Inhibitors, 2020-2021.
3. M. Sc. Student: *Sarah Meknas*, Optimization of *N*-Substituted-6-Chloro-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2020-2021.
4. M. Sc. Student: *Batool Allahwani*, Design, Synthesis, and Biological Evaluation of *N*-Substituted-7-Methyl-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2020-2021.
5. M. Sc. Student: *Reem Ahmad Isleem*, Design, Synthesis, and Biological Evaluation of Nitrated *N*-Substituted-4-Hydroxy-2-Quinolone-3 Carboxamides as PI3K $\alpha$  Inhibitors, 2019-2021.
6. M. Sc. Student: *Rawan Amer Haroon*, Chlorinated Derivatives of *N*-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2019-2020.
7. M. Sc. Student: *Tahrer Fadhil Abd AL-Bo Aswad*, Synthesis and Biological Evaluation of *N*-Substituted-4-Hydroxy-8-Methyl-2-Quinolone-3-Carboxamide Derivatives as PI3K $\alpha$  Inhibitors, 2018-2019.
8. M. Sc. Student: *Abdullah Musa Abdel Fattah Abdullah*, Methoxylated Derivatives of *N*-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2018-2019.
9. M. Sc. Student: *Asma Ali Jumah*, Design, Synthesis, and Biological Evaluation of *N*-Substituted-4-Hydroxy-8-Methoxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2018-2019.
10. M. Sc. Student: *Bara'a Ahmad Al-Azaideh*, Design, Synthesis, and Biological Evaluation of Benzophenone Hydrazone Derivatives as PI3K $\alpha$  Inhibitors, 2018-2019.



11. M. Sc. Student: *Hla Hasan Samarat*, Design, Synthesis, and Biological Evaluation of Fluorinated *N*-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2018-2019.
12. M. Sc. Student: *Shaima' Emad Hasan*, Design, Synthesis, and Biological Evaluation of *N*-Substituted-4-Hydroxy-6-Methyl-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors, 2017-2018.
13. M. Sc. Student: *Nisreen Shaban Hamadeh*, Optimization of 4-Hydroxy-2-Quinolone-3-Carboxamide Core Nucleus Targeting PI3K $\alpha$  Inhibition, 2016-2017.
14. M. Sc. Student: *Ameerah Saeed Ibrahim*, Optimization and Synthesis of Benzoin Derivatives as PI3K $\alpha$  Inhibitors, 2015-2016.
15. M. Sc. Student: *Fatmeh Mahmoud Tarawneh*, Design, Synthesis, and Biological Evaluation of Benzoin Schiff Bases as Antitumor Agents, 2015-2016.
16. M. Sc. Student: *Dalal Yousef Masalha*, Phenanthridines: Design, Synthesis, and Biological Evaluation as Potential DPP-IV Inhibitors, 2015-2016.
17. M. Sc. Student: *Bayan Salah Hishmah*, Design, Synthesis, and Biological Evaluation of Novel PI3K  $\alpha$  Inhibitors, 2013-2014.
18. M. Sc. Student: *Musaab Mahmoud Saada*, Pharmacophore-Based Screening and Identification of Novel Phosphoinositide 3-kinase (PI3K $\alpha$ ) Inhibitors, 2013-2014.

• ***Auditor of Internal Defense Performance***

1. 2022, May 30<sup>th</sup> (Observer) "Economic Modeling For Jordan of the Cost-Efficiency and Associated Expanded Treatment Access of Conversion to Rituximab Biosimilar from Reference Rituximab" (M. Sc. Student: Hala Hisham Abu Halawa; Al-Zaytoonah University of Jordan College of Pharmacy)
2. 2022, August 24<sup>th</sup> (Observer) "Development of Optimization of Antimicrobial Nanoemulsion-Loaded into Two Bigels: A Comparative Study" (M. Sc. Student: Ola Abu Al-Ata; Al-Zaytoonah University of Jordan College of Pharmacy)
3. 2022, August 30<sup>th</sup> (Observer) "An Intelligent Detection Approach for Drug Abuse in Arabic Social Media Posts" (M. Sc. Student: Amani AbdelQader; Al-Zaytoonah University of Jordan College of Science & Information Technology-Department of Computer Science)

**B. External**

1. Ph.D. Student: *Reem Ahmad Al-Janabi (The University of Jordan College of Pharmacy)*, Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer, 2019-2021.

- ***Mentoring of Graduate Research***

1. M. Sc. Student: *Hanin Mohammad K. Kalloush*, Design, Synthesis, and *In Vivo* Biological Evaluation of Novel Benzimidazole-2-Carboxamide Derivatives as Antihyperlipidemic Agent, 2015-2016.
2. M. Sc. Student: *Haneen Muneer Mohammad Abu Zaid*, Design, Synthesis, and *In Vivo* Biological Evaluation of Imidazole-5-Carboxamide Derivatives as Lipoprotein Lipase Activators, 2015-2016.
3. M. Sc. Student: *Sarah Mohammad Ahmad Al-Rawashdeh*, Fluorinated Benzamides: Design, Synthesis and Biological Evaluation as Potential CETP Inhibitors, 2015-2016.
4. M. Sc. Student: *Nisreen Nazmi Haj Ahmad*, Synthesis and Antihyperlipidemic Properties of Novel *N*-(4-Benzoylphenyl) Pyrrole-2-Carboxamide Derivatives, 2014-2016.
5. M. Sc. Student: *Amneh Mahmoud Abu Al-Inin*, Synthesis and Biological Evaluation of Novel 5-Bromo Indole-2-Carboxamide Derivatives, 2014-2016.
6. M. Sc. Student: *Hamada Mansour Abd El-Aal Abd El-Aziz*, Synthesis and Biological Evaluation of Substituted Fluorinated Alkyloxy Benzenamide as Potential CETP inhibitors, 2014-2015.
7. M. Sc. Student: *Dania Mohammed Nazer Al kabbani*, Synthesis and Biological Evaluation of Novel *N*-Benzoylphenyl-2-Furamide Derivatives, 2014-2015.

- ***Examining of Graduate Research***

1. 2022, September 4<sup>th</sup> (*External Examiner*) "In Vitro Evaluation of Selective Serotonin Reuptake Inhibitors (SSRI) as Anticancer Agents" (M. Sc. Student: Esraa Kathim Jaradat; *The University of Jordan College of Pharmacy*).
2. 2022, September 4<sup>th</sup> (*External Examiner*) "Exploring the Molecular Mechanisms Underlying the Anti-tumorigenic effect of Angiotensin Receptor Blockers





- (ARB)” (M. Sc. Student: Raneem Subhi Atiyah; *The University of Jordan College of Pharmacy*).
3. 2022, September 1<sup>st</sup> (*External Examiner*)” Insulin Detemir: Potential Drug Interactions and Efforts to Prolong Action” (Ph.D. Student: Dua’a Ghazi Farah; *The University of Jordan College of Pharmacy*).
  4. 2022, May 31<sup>st</sup> (*Internal Examiner*)” New Meta-Fluorinated Diaryl Sulfonamides: Synthesis and *In Vitro* Study as Promising Cholesteryl Ester Transfer Protein Inhibitors” (M. Sc. Student: Yasmin Mahmoud Selim Ibrahim; *Al-Zaytoonah University of Jordan College of Pharmacy*)
  5. 2022, May 29<sup>th</sup> (*External Examiner*)” Repurposing of Phosphodiesterase Isoenzyme 5 (PDE-5) Inhibitors for Cancer Treatment: An *In Vitro* Study” (M. Sc. Student: Rola Haider Al-Omari; *The University of Jordan College of Pharmacy*).
  6. 2022, January 16<sup>th</sup> (*Internal Examiner*)” Fluorinated Benzene Sulfonamides as Potential Cholesteryl Ester Transfer Protein Inhibitors: Synthesis and Subsequent *In Vitro* Validation” (M. Sc. Student: Hamza Mahmoud Al-Shaiah; *Al-Zaytoonah University of Jordan College of Pharmacy*)
  7. 2022, January 3<sup>rd</sup> (*External Examiner*)” Exploring Novel HCAVII Inhibitors as Potential Antiepileptic Agents” (M. Sc. Student: Numan Aluneisi; *The University of Jordan College of Pharmacy*).
  8. 2021, December 29<sup>th</sup> (*External Examiner*)” Molecular Biological Evaluation of MAO-A Inhibitors Efficacy Against Breast Cancer” (M. Sc. Student: Aseel Abdallah Issa Alkhawaldeh; *The University of Jordan College of Pharmacy*).
  9. 2021, August 30<sup>th</sup> (*External Examiner*)” Exploring the Role of Sodium-glucose Cotransporter as a New Target for Cancer Therapy” (M. Sc. Student: Ahmad Mohammad Issa; *The University of Jordan College of Pharmacy*).
  10. 2021, August 30<sup>th</sup> (*External Examiner*)” Synthesis, Characterization, Molecular Docking, and Biological Evaluation of New Derivatives of 1,2-Dihydroquinoline-3-Carboxamide as Potential Anticancer Agents” (M. Sc. Student: Dania Nasser; *The University of Jordan Chemistry Department*)
  11. 2021, August 25<sup>th</sup> (*Internal Examiner*)” Diaryl Sulfonamides: Synthesis, Characterization, and *In Vitro* Biological Evaluation as CETP Inhibitors” (M. Sc. Student: Azhar Mohammad Salem Shalluf; *Al-Zaytoonah University of Jordan College of Pharmacy*).
  12. 2021, May 26<sup>th</sup> (*External Examiner*)” Molecular Modeling Approach to Identify Novel Alpha-Amylase Inhibitors as Potential Antidiabetic Drugs” (M. Sc.



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

Student: Taima' Walid Abdelmajid Chaban; *University of Petra College of Pharmacy*).

13. 2021, May 20<sup>th</sup> (*Internal Examiner*)” Synthesis and Biological Evaluation of Aromatic Sulfonamides as Novel Cholesteryl Ester transfer Protein Inhibitors ” (M. Sc. Student: Manal Jamal Asa'ad; *Al-Zaytoonah University of Jordan College of Pharmacy*).
14. 2021, May 19<sup>th</sup> (*External Examiner*)” *In silico* Screening and Experimental Validation of Novel MexAB-OprM Efflux Pump Inhibitors of *Pseudomonas Aeruginosa*” (M. Sc. Student: Malak Jamal Hajar; *University of Petra College of Pharmacy*).
15. 2021, May 18<sup>th</sup> (*External Examiner*)” An In Vitro Study of the Implication and Efficacy of Aromatase Inhibitors Combination and Mono-Chemotherapy against Lung Cancer” (M. Sc. Student: Bayan Amjad Rahal; *The University of Jordan College of Pharmacy*).
16. 2020, December 22<sup>nd</sup> (*External Examiner*)” Antiinflammatory Properties of Lipophilic Fluoroquinolones-Based Scaffold against Cancer Cell Lines” (M. Sc. Student: Tasneem Khalid Badawi Alhallaq; *The University of Jordan College of Pharmacy*).
17. 2020, December 20<sup>th</sup> (*External Examiner*)” Investigations into The Molecular Mechanisms Underlying the Anti-proliferative and Anti-tumorigenesis Activities of COX2 Inhibitors against Hepatocellular Carcinoma Cells” (M. Sc. Student: Sara Ahmad Khliefat; *The University of Jordan College of Pharmacy*).
18. 2020, December 17<sup>th</sup> (*External Examiner*)” Exploration of anti-proliferative and anti-tumorigenesis activities of monoamine oxidase-A (MAO-A) inhibitors against colorectal cancer and investigation into their underlying molecular mechanisms” (M. Sc. Student: Husam Ahmad Abdel-Karim Al-Salamat; *The University of Jordan College of Pharmacy*).
19. 2020, November 22<sup>nd</sup> (*External Examiner*) “In vitro evaluation of potential therapeutic benefits of selective estrogen modulators (SERMs) for lung cancer treatment” (M.Sc. Student: Lina Adnan Al Sous; *The University of Jordan College of Pharmacy*).
20. 2020, January 9<sup>th</sup> (*External Examiner*) “Evaluation of Selected Natural Products to Overcome Cisplatin Resistance in Breast Cancer: an *in vitro* and *in vivo* study” (M. Sc. Student: Ali Hussein Al-Rufaye; *Applied Science University College of pharmacy*).





QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

21. 2019, May 9<sup>th</sup> (*Internal Examiner*) "Synthesis, Characterization, and *In-Vitro* Biological Evaluation as Potential DPP-IV Inhibitors" (M. Sc. Student: *Ebtisam Abdulkareem Ali Alwarafi*; *Al-Zaytoonah University of Jordan College of Pharmacy*).
22. 2019, April 21<sup>st</sup> (*External Examiner*) "Synthesis and Anticancer Activity of Novel Pyridoquinoxaline Derivatives" (M. Sc. Student: *Alaa Saeed Tabaza*; *The University of Jordan College of Pharmacy*)
23. 2019, March 11<sup>th</sup> (*Internal Examiner*) "Synthesis and Evaluation of Curcumin-loaded Polyphenol Nanoparticles as a Potential Anti-cancer Nanomedicine" (M. Sc. Student: *Tahany "Mohammad Tayseer" Ahmad Al Debsi*; *Al-Zaytoonah University of Jordan College of Pharmacy*).
24. 2018, June, 6<sup>th</sup> (*External Examiner*) "Molecular Modeling and Screening of AcrAB-TolC Efflux Pump Inhibitors of *Escherichia coli*" (M. Sc. Student: *Ala'a Rae'd Al-Dajani*; *University of Petra Faculty of Pharmacy and Medical Sciences*)
25. 2017, December 14<sup>th</sup> (*External Examiner*) "Synthesis, Characterization, and Antimicrobial Evaluation of New Substituted 1*H*-Indole-2-Carboxamide Derivatives" (M. Sc. Student: *Alaa Mahmoud Al-Shamaileh*; *The University of Jordan Chemistry Department*)
26. 2017, April 26<sup>th</sup> (*External Examiner*) "Towards The Discovery of New Inhibitors Against The Highly Conserved Protein Polyphosphate Kinase (PPK1) Followed by Validation Against Relevant Bacterial Species" (M. Sc. Student: *Rasha Mohammad Bashatwah*; *The University of Jordan College of Pharmacy*)
27. 2016, August 31<sup>st</sup> (*Internal Examiner*) " Design, Synthesis, and *in vivo* Biological Evaluation of Novel Benzimidazole-2-carboxamide Derivatives as Antihyperlipidemic Agents" (M. Sc. Student: *Hanin Mohammad K. Kallos*; *Al-Zaytoonah University of Jordan College of Pharmacy*)
28. 2016, July 18<sup>th</sup> (*Internal Examiner*) "Influence of Polymer Type and Its Molecular Weight on the Release of Quercetin from Polymeric Micelles" (M. Sc. Student: *Aya Sadat Taha Alsadi*; *Al-Zaytoonah University of Jordan College of Pharmacy*)
29. 2016, January 20<sup>th</sup> (*Internal Examiner*) "Fluorinated Benzamides: Design, Synthesis and Biological Evaluation as Potential CETP Inhibitors" (M. Sc. Student: *Sarah Mohammad Ahmad Al-Rawashdeh*; *Al-Zaytoonah University of Jordan College of Pharmacy*)
30. 2016, January 18<sup>th</sup> (*Internal Examiner*) "Synthesis and Antihyperlipidemic Properties of Novel *N*-(4-Benzoylphenyl) Pyrrole-2-Carboxamide Derivatives"



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

(M. Sc. Student: *Nisreen Nazmi Haj Ahmad*; Al-Zaytoonah University of Jordan College of Pharmacy)

31. 2015, December 31<sup>st</sup> (*Internal Examiner*) "Synthesis and Biological Evaluation of Novel 5-Bromo Indole-2-Carboxamide Derivatives" (M. Sc. Student: *Amneh Mahmoud Abu Al-Inin*; Al-Zaytoonah University of Jordan College of Pharmacy)
32. 2015, May 21<sup>st</sup> (*Internal Examiner*) "Synthesis and Biological Evaluation of Substituted Fluorinated Alkyloxy Benzenamide as Potential CETP inhibitors" (M. Sc. Student: *Hamada Mansour Abd El-Aal Abd El-Aziz*; Al-Zaytoonah University of Jordan College of Pharmacy)
33. 2013, August 18<sup>th</sup> (*Internal Examiner*) "Design, Synthesis, and Biological Evaluation of a New Series of Potential CETP Inhibitors" (M. Sc. Student: *Mohamed Galal Saad El Hendy*; Al-Zaytoonah University of Jordan College of Pharmacy)
34. 2013, October 10<sup>th</sup> (*Internal Examiner*) "Design, Synthesis, and Biological Evaluation of a New Series of Potential DPP IV Inhibitors" (M. Sc. Student: *Zainab Jarekji*; Al-Zaytoonah University of Jordan College of Pharmacy)

- ***Supervision of Undergraduate Students:***

1. B. Sc. Students: *Hakam M. Al Aqabani* & *Ikhlas Altaweel*, Molecular Docking Studies on Epidermal Growth Factor Receptor (EGFR), 2016.

*Hakam & Ikhlas* achieved the Second Place in Splendor of Pharmacists (SOP) Competition- Medicinal Chemistry (Structure-Based Drug Design) Section.

## **11. Grants**

1. Design, Synthesis, and Biological Evaluation of Novel Monoamine Oxidase-A Inhibitors Targeting Lung Cancer Followed by Investigation of the Molecular Mechanisms using Mass Spectrometry-based Metabolomics and IR-Microspectroscopy, 2020-2022, Abdul Hameed Shoman Foundation, 20,000 JD.

*Sanaa K. Bardaweel, Lina Dahabiyeh, Dima A. Sabbah*



2. Design, Synthesis, and Biological Evaluation of CETP and PI3K $\alpha$  Inhibitors, 2020-2021, Al-Zaytoonah University of Jordan, the Deanship of Scientific Research, 24,000 JD.

*Reema Abu Khalaf & Dima A. Sabbah*

3. The Development, Application, and Experimental Validation of an Integrative Informatics Methodology to Identify Biomarkers, Pharmacological Targets and Pharmacotherapy for COVID-19, 2020-2022, Al-Zaytoonah University of Jordan, the Deanship of Scientific Research, 55,000 JD.

*Rima Hajjo & Dima A. Sabbah*

4. Design, Synthesis, and Biological Evaluation of Novel Monoamine Oxidase-A Inhibitors Targeting Lung Cancer, 2020-2022, King Abdullah II Fund for Development, 15,000 JD.

*Sanaa K. Bardaweel, Dima A. Sabbah, Lina Dahabiyeh*

5. Design, Synthesis, and Biological Evaluation of PI3K $\alpha$  and EGFR Inhibitors Targeting Colon and Breast Cancer, 2018-2020, Scientific Research Support Fund, The Higher Education Ministry of Jordan, 56,445 JD. And, Al-Zaytoonah University of Jordan, the Deanship of Scientific Research, 20,000 JD.

*Dima A. Sabbah, Sanaa K. Bardaweel, Kamal Sweidan, Reema Abu Khalaf, Eveen Al-Shalabi, Ghassan Abu Sheikha, Tariq Al Qirim*

6. Design, Synthesis, and Biological Evaluation of a New Series of CETP Inhibitors, 2017-2019, Al-Zaytoonah University of Jordan, the Deanship of Scientific Research, 40,000 JD.

*Reema Abu Khalaf, Dima A. Sabbah, Eveen Al-Shalabi, Ghassan Abu Sheikh*

7. Design, Synthesis, and Biological Evaluation of PI3Ks Inhibitors, 2014-2016, the Deanship of Scientific Research, Al-Zaytoonah University of Jordan, 108,000 JD.

*Dima A. Sabbah, Ghassan Abu Sheikha, Tariq Al-Qirim, Reema Abu Khalaf*



8. 3-Benzylamino-Benzamides: Design, Synthesis, and Biological Evaluation as Novel CETP Inhibitors, 2015-2016, the Deanship of Scientific Research, Al-Zaytoonah University of Jordan, 38,100 JD.

*Reema Abu Khalaf, Ghassan Abu Sheikh, **Dima A. Sabbah**, Eveen Al-Shalabi*

9. Synthesis, Characterization and Biological Evaluation for some PI3Ks Inhibitors, 2013-2015, Hamdi Mango Center for Scientific Research, The University of Jordan, 5000 JD.

*Kamal Sweidan, Ghassan Abu Sheikh, **Dima A. Sabbah***

#### 10. **Membership of Committees**

- 2022, the Chair of the Promotion Evaluation Committee.
- 2021, Promotion Evaluation Committee Member.
- 2019-now Post-Graduate Studies Committee.
- 2019-2020, Pharmacy Curriculum Plan Committee.
- 2014-2015, 2017- 2019, the Chair of the Laboratory and Devices Committee.
- 2017-now, Scientific Research Committee Member.
- 2015, Scientific Committee Member of **ZTIPC 2015** conference.
- 2013-2014, the Chair of the Conference Committee.

#### 11. **Professional and Scientific Meetings**

1. Al-Zaytoonah 8<sup>th</sup> International Pharmaceutical Conference (ZIPC 2022) "Promising Prospects in Pharmaceutical Sciences", October 18-19<sup>th</sup> 2022, Amman, Jordan. Oral Presentation: Progress in the Design and Development of Phosphoinositide-3-Kinase (PI3K $\alpha$ ) Inhibitors.

**Dima A. Sabbah**

2. The Jordan Pharmaceutical Students' Association (JPSA) Third National Symposium, September 17-19<sup>th</sup> 2021, Virtual Oral Presentation: Research Ethics.

**Dima A. Sabbah**



3. The University of Jordan School of Pharmacy, "Recent *Updates in Pharmacy and Pharmaceutical Sciences*", April 7-8<sup>th</sup> 2021, Amman, Jordan. Oral Presentation: Structure-Based Drug Design of *N*-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Phosphoinositide-3-Kinase (PI3K $\alpha$ ) Inhibitors.

**Dima A. Sabbah**, Bayan Hishmah, Kamal Sweidan, Sanaa Bardaweel, Murad AlDamen, Haizhen A. Zhong, Reema Abu Khalaf, Ameerah (Hasan Ibrahim), Tariq Al-Qirim, Ghassan Abu Sheikha, Mohammad S. Mubarak

4. RBCs Scientific Research Workshop, October 23<sup>rd</sup> 2020, Virtual Oral Presentation: Research Ethics.

**Dima A. Sabbah**

5. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Oral Presentation: Design and Synthesis of Phosphoinositide-3-Kinase (PI3K $\alpha$ ) Inhibitors.

**Dima A. Sabbah**, Sanaa K. Bardaweel, Wamidh H. Talib, Khalid M. Alqaisi, Kamal Sweidan, Murad AlDamen, Eveen Al-Shalabi, Reema Abu Khalaf, Ghassan Abu Sheikha, Tariq Al-Qirim, Haizhen A. Zhong

6. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: Structure-Based Design: Synthesis and Biological Evaluation of *N*-Substituted-4-Hydroxy-6-Methoxy-2-Quinolone-3-Carboxamide Derivatives as PI3K $\alpha$  Inhibitors.

Abdullah M. Abdullah, **Dima A. Sabbah**, Sanaa Bardaweel, Ghassan Abu Sheikha, Eveen Al-Shalabi, Kamal Sweidan, Reema Abu Khalaf, Tariq Al-Qirim

7. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: *N*-Substituted-4-Hydroxy-8-Methoxy-2-Quinolone-3-Carboxamides: Design, Synthesis, and Biological Evaluation as PI3K $\alpha$  Inhibitors.



Asma A. Jumah, **Dima A. Sabbah**, Sanaa Bardaweel, Kamal Sweidan, Eveen Al-Shalabi, Reema Abu Khalaf, Ghassan Abu Sheikha, Tariq Al-Qirim

8. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: Design, Synthesis, and Biological Evaluation of *N*-Substituted-4-Hydroxy-8-Methyl-2-Quinolone-3-Carboxamide Derivatives as PI3K $\alpha$  Inhibitors.

Taher F. Al-Bo Aswad, **Dima A. Sabbah**, Sanaa Bardaweel, Ghassan Abu Sheikha, Kamal Sweidan, Reema Abu Khalaf, Eveen Al-Shalabi, Tariq Al-Qirim

9. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: *N*-Substituted-4-Hydroxy-6-Nitro-2-Quinolone-3-Carboxamides: Design, Synthesis, and Biological Evaluation as PI3K $\alpha$  Inhibitors.

Nisreen S. Hamadeh, **Dima A. Sabbah**, Sanaa Bardaweel, Wamidh Talib, Reema Abu Khalaf, Eveen Al-Shalabi, Kamal Sweidan, Ghassan Abu Sheikha, Tariq Al-Qirim

10. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: *N*-Substituted-4-Hydroxy-6-Methyl-2-Quinolone-3-Carboxamides: Design, Synthesis, and Biological Evaluation as PI3K $\alpha$  Inhibitors.

Shaima' E. Hasan, **Dima A. Sabbah**, Sanaa Bardaweel, Reema Abu Khalaf, Eveen Al-Shalabi, Kamal Sweidan, Ghassan Abu Sheikha, Tariq Al-Qirim

11. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2019) "Future of Pharmaceutical Sciences", November 6-7<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: *N*-Substituted-4-





Hydroxy-6-Fluoro-2-Quinolone-3-Carboxamides: Design, Synthesis, and Biological Evaluation as PI3K $\alpha$  Inhibitors.

Hla H. Samarat, **Dima A. Sabbah**, Sanaa Bardaweel, Eveen Al-Shalabi, Reema Abu Khalaf, Kamal Sweidan, Ghassan Abu Sheikha, Tariq Al-Qirim

12. Gordon Research Conference "Stem Cells and Cancer", March 24-29<sup>th</sup> 2019, Ventura Beach Marriott, Ventura, CA United States. Poster Presentation: Phosphatidylinositol 3-Kinase Alpha (PI3K $\alpha$ ) Enzyme in Cancer Progression: Design, Synthesis, and Biological Evaluation of Novel Molecules Targeting the PI3K $\alpha$  as Anticancer Agents.

Ghassan Abu Sheikha, **Dima Sabbah**, Shaima' Hasan, Reema Abu Khalaf, Sanaa' Bardaweel, Kamal Sweidan, Eveen Al-Shalabi, Tariq Al-Qirim, Wamidh Talib, Haizhen A. Zhong

13. ASU-Pharmacy Fourth Symposium "Recent Trends in Postgraduate Research", January 5-6<sup>th</sup> 2019, Amman, Jordan. Poster Presentation: Design, Synthesis, and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.

Shaima' Emad Hasan, Ameerah Hasan Ibrahim, **Dima A. Sabbah**, Wamidh H. Talib, Khalid M. Alqaisi, Kamal Sweidan, Sanaa K. Bardaweel, Ghassan Abu Sheikha, Haizhen A. Zhong, Eveen Al-Shalabi, Reema Abu Khalaf, Mohammad S. Mubarak

14. ASU-Pharmacy Fourth Symposium "Recent Trends in Postgraduate Research", January 5-6<sup>th</sup> 2019, Amman, Jordan. Oral Presentation: Structure-Based Design: Synthesis and Biological Evaluation of *N*-Substituted-4-Hydroxy-6-Nitro-2-Quinolone-3-Carboxamides as Potential PI3K $\alpha$  Inhibitors

Nisreen S. Hamadeh, **Dima A. Sabbah**, Reema Abu Khalaf, Wamidh H. Talib

15. BIT's 16th Annual Congress of International Drug Discovery Science and Technology (IDDST) "Rethinking the Next Big Things in Pharma Innovations". Oral presentation: Synthesis, biological evaluation and



molecular modeling study of substituted benzyl benzamides as CETP inhibitors, August 16-19, 2018, Boston, USA.

Reema Abu Khalaf, **Dima A. Sabbah**, E Al-Shalabi, S Bishtawi, G Albadawi, G Abu Sheikha

16. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2017) “*New Horizons in Pharmaceutical Research*”, November 29-30<sup>th</sup> 2017, Amman, Jordan. Oral Presentation: Pharmacophore Based-Design of Phosphoinositide-3-Kinase (PI3K $\alpha$ ) Inhibitors.

**Dima A. Sabbah**, Bayan Hishmah, Kamal Sweidan, Sanaa Bardaweel, Murad AlDamen, Haizhen A. Zhong, Reema Abu Khalaf, Ameerah (Hasan Ibrahim), Tariq Al-Qirim, Ghassan Abu Sheikha, Mohammad S. Mubarak

17. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2017) “*New Horizons in Pharmaceutical Research*”, November 29-30<sup>th</sup> 2017, Amman, Jordan. Poster Presentation: Structure-Based Design, Synthesis, and Biological Evaluation of Benzoin Schiff Bases as Potential Antitumor Agents

Fatima Al-Tarawneh, **Dima A. Sabbah**, Wamidh Talib, Kamal Sweidan, Sanaa Bardaweel, Eveen Al-Shalabi, Haizhen A. Zhong, Ghassan Abu Sheikha, Reema Abu Khalaf, Mohammad S. Mubarak

18. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2017) “*New Horizons in Pharmaceutical Research*”, November 29-30<sup>th</sup> 2017, Amman, Jordan. Poster Presentation: Ligand-Based Design: Synthesis and Optimization of Benzoin Scaffold as Phosphoinositide-3-Kinase (PI3K $\alpha$ ) Inhibitors

Ameerah (Hasan Ibrahim), **Dima A. Sabbah**, Wamidh Talib, Kamal Sweidan, Sanaa Bardaweel, Ghassan Abu Sheikha

19. BIT's 15<sup>th</sup> Annual Congress of International Drug Discovery Science and Technology (IDDST), July 25-27<sup>th</sup> 2017, Osaka, Japan. Oral Presentation:



Fluorinated Benzamides: Molecular Docking and Pharmacophore Modeling Studies Targeting CETP Inhibition

Dr. Reema Abu Khalaf\*, Sarah Al-Rawashdeh, **Dima Sabbah**, Ghassan Abu Sheikhha

20. ASU-Pharmacy Third Symposium "Recent Trends in Postgraduate Research", April 15-16<sup>th</sup> 2017, Amman, Jordan. Poster Presentation: *N*-Substituted- 4-Hydroxy-2-Quinolone-3-Carbox- amides as Potential PI3K $\alpha$ . The Poster is awarded the *Third Place in Postgraduate Poster Competition*.

Ameerah (Hasan Ibrahim), Bayan Hishmah, **Dima A. Sabbah**, Kamal Sweidan, Sanaa Bardaweel, Murad AlDamen, Reema Abu Khalaf, Haizhen A. Zhong, Tariq Al-Qirim, Ghassan Abu Sheikhha

21. Gordon Research Conference: Mammalian DNA Repair, February 19-24<sup>th</sup> 2017, Ventura, CA, USA. Poster Presentation: Structure-Based Drug Design, Synthesis, X-ray Crystallography, and Biological Evaluation of *N*-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as PI3K $\alpha$  Inhibitors.

Ghassan Abu Sheikhha, **Dima A. Sabbah**, Bayan Hishmah, Kamal Sweidan, Sanaa Bardaweel, Murad AlDamen, Haizhen A. Zhong, Ameerah (Hasan Ibrahim), Reema Abu Khalaf, Tariq Al-Qirim

22. The University of Jordan School of Pharmacy, The 4<sup>th</sup> international Conference & the 2<sup>nd</sup> Conference of the Association of Faculties of Pharmacy at Jordanian Universities" *Excellence in Pharmacy Education & Research: A Quality Approach*", October 25-27<sup>th</sup> 2016, Amman, Jordan. Oral Presentation: Modeling The Protonation States of  $\beta$ -secretase Binding Pocket Employing Molecular Dynamic Simulations and Docking Studies

**Dima A. Sabbah** and Haizhen Zhong

23. The University of Jordan School of Pharmacy, The 4<sup>th</sup> international Conference & the 2<sup>nd</sup> Conference of the Association of Faculties of Pharmacy at Jordanian Universities" *Excellence in Pharmacy Education & Research: A Quality Approach*", October 25-27<sup>th</sup> 2016, Amman, Jordan. Poster Presentation:



Structure-Based Drug Design, Synthesis, and Biological Evaluation of Benzoin Analogues as Potential PI3K $\alpha$  Inhibitors.

**Dima A. Sabbah**, Musaab Saada, Reema Abu Khalaf, Sanaa Bardaweel, Kamal Sweidan, Tariq Al-Qirim, Amani Al-Zughier, Heba Abdel Halim, Ghassan Abu Sheikha

24. ASU-Pharmacy Second Symposium "*Recent Trends in Postgraduate Research*", December 5-6<sup>th</sup> 2015, Amman, Jordan. Poster Presentation: Structure-Based Drug Design, Synthesis, and Biological Evaluation of Novel Benzoin Derivatives as anticancer agents

Musaab Saada, **Dima A. Sabbah**, Reema Abu Khalaf, Sanaa Bardaweel, Kamal Sweidan, Tariq Al-Qirim, Amani Al-Zughier, Heba Abdel Halim, Ghassan Abu Sheikha

25. Al-Zaytoonah University of Jordan and the University of Toledo International Pharmaceutical Conference (ZTIPC 2015) "*Frontiers in the pharmaceutical sciences and pharmacy practice: A global perspective*", October 21-23<sup>rd</sup> 2015, Amman, Jordan. Oral Presentation: From Hit to Lead: Structure-Based Drug Design, Synthesis, and Biological Evaluation of Novel Benzoin Derivatives as PI3K $\alpha$  Inhibitors.

**Dima A. Sabbah**, Musaab Saada, Reema Abu Khalaf, Sanaa Bardaweel, Kamal Sweidan, Tariq Al-Qirim, Amani Al-Zughier, Heba Abdel Halim, Ghassan Abu Sheikha

26. Computer Aided Drug Design: New Frontiers in computer-Aided Drug Design, July 19-24<sup>th</sup> 2015, VT, USA. Poster Presentation: Design, Synthesis and Biological Evaluation of Novel PI3K Alpha Inhibitors with Potential Anti-Cancer Activity.

Ghassan Abu Sheikha, **Dima A. Sabbah**, Reema Abu Khalaf, Tariq Al-Qirim, Sanaa Bardaweel

27. Ligand Recognition & Molecular Gating: Structure and Dynamics of Ion Channels, G-Protein Coupled Receptors, and Solute Transporters, March 23-



28<sup>th</sup> 2014, Ventura, CA. Poster Presentation: Design, Synthesis, and Biological Evaluation of a New Series of Potential CETP Inhibitors.

*Ghassan Abu Sheikha, Reema Abu Khalaf, **Dima A. Sabbah***

28. The 15<sup>th</sup> Scientific Congress of the Jordanian Pharmacists Association, April 3-5<sup>th</sup> 2014, Amman, Jordan. Oral Presentation: Structure-Based Drug Design, Synthesis, and Biological Evaluation of a Novel Scaffold for PI3K $\alpha$  Inhibitors.

*Bayan S. Hishmah, **Dima A. Sabbah**, Ghassan M. Abu Sheikha*

29. The 15<sup>th</sup> Scientific Congress of the Jordanian Pharmacists Association, April 3-5<sup>th</sup> 2014, Amman, Jordan. Poster Presentation: Ligand-Based Drug Design: Pharmacophore Model and Database Search of Novel PI3K $\alpha$  Inhibitors.

***Dima A. Sabbah**, Neka A. Simms, Wang Wang, Yuxiang Dong, Edward L. Ezell, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong*

30. The Bioinformatics Symposium, March 4<sup>th</sup> 2014, Zarqa University, Amman, Jordan. Oral Presentation: Structure-Based Drug Design: Molecular Docking Studies of Phosphoinositide-3-Kinases.

***Dima A. Sabbah**, Jonathan L. Vennerstrom, and Haizhen Zhong*

31. The Cancer Symposium Day, May 15<sup>th</sup> 2013, Al-Zaytoonah University of Jordan, Amman, Jordan. Oral Presentation: *N*-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R PI3K $\alpha$ .

***Dima A. Sabbah**, Neka A. Simms, Wang Wang, Yuxiang Dong, Edward L. Ezell, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong*

32. The 47<sup>th</sup> ACS Midwest Regional Meeting, October 24-27<sup>th</sup> 2012, Omaha, NE. Poster Presentation: Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.

***Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen A. Zhong*



33. The 44<sup>th</sup> annual PGSRM, June 7-9<sup>th</sup> 2012, University of Nebraska Medical Center, Omaha, NE. Poster Presentation: Structure-based drug design, synthesis, and biological evaluation of a novel scaffold for PI3K $\alpha$  inhibitors.

**Dima A. Sabbah**, Neka A. Simms, Wang Wang, Yuxiang Dong, Edward L. Ezell, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong

34. The Nebraska Academy of Sciences, April 20<sup>th</sup> 2012, Lincoln, NE. Oral Presentation: Synthesis, biological evaluation, and molecular docking studies of novel phosphoinositide-3-kinase (PI3K $\alpha$ ) inhibitors.

**Dima A. Sabbah**, Neka A. Simms, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong

35. ACS Denver National Meeting, August 28 – September 1<sup>st</sup> 2011, Denver, CO. Poster Presentation: Investigation of phosphoinositide 3-kinases binding pocket using mm-pbsa.

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen A. Zhong

36. TeraGrid '11, July 18-21<sup>st</sup> 2011, Salt Lake City, Utah. Poster Presentation: Modeling of PI3K using Molecular Dynamic Simulations on UNL Cluster.

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen A. Zhong

37. The Nebraska Academy of Sciences, April 15<sup>th</sup> 2011, Lincoln, NE. Oral Presentation: Determination of  $\beta$ -secretase binding site charge employing MD simulation and molecular docking.

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen A. Zhong

38. ACS Anaheim National Meeting, March 27-30<sup>th</sup> 2011, Anaheim, CA. Poster Presentation: Discovery of Novel Inhibitors of Phosphoinositide-3-Kinases.

**Dima A. Sabbah**, Neka A. Simms, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong





39. The 45th Midwest Regional Meeting of the ACS, October 27-30<sup>th</sup> 2010, Wichita, KS. Poster Presentation: Pharmacophore Model, Database Search, Docking Study and Biological Assays for Novel PI3K $\alpha$  Inhibitors.

**Dima A. Sabbah**, Neka A. Simms, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen A. Zhong

40. AAPS Graduate Student Symposium in Drug Design and Discovery, November 8-12<sup>th</sup> 2009, Los Angeles, CA. Oral and Poster Presentations: Selectivity Studies of PI3K Inhibitors by Molecular Docking. This work is honored by the AAPS. "Graduate Student Symposium Award in Drug Design & Discovery"

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen Zhong

41. The Nebraska Academy of Sciences, April 17<sup>th</sup> 2009, Lincoln, NE. Oral Presentation: Homology Modeling and Docking Studies of PI3K $\alpha/\gamma$ .

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen Zhong

42. The 43<sup>rd</sup> ACS Midwest Regional Meeting, October 8-11<sup>th</sup> 2008, Kearney, NE. Oral Presentation: Computational Studies and Inhibitors Design of PI3K $\alpha$ .

**Dima A. Sabbah**, Jonathan L. Vennerstrom, Haizhen Zhong

## **12. Participation in or organization of curricular and/or extra-curricular activities**

- May 15, 2013, Organizer of One Day Symposium on Cancer, entitled "Cancer: Causes, Diagnosis, and Treatment".

## **13. Journal peer reviewer**

- Applied Microbiology and Biotechnology
- Archiv der Pharmazie
- Analytical Chemistry Letters
- Anti-Cancer Agents in Medicinal Chemistry
- Bioorganic Medicinal Chemistry Letter
- Bioorganic Chemistry



- Bentham Medicinal Chemistry
- Cancers
- Current Topics in Medicinal Chemistry
- Diagnostics
- European Journal of Medicinal Chemistry
- Genetic Engineering and Biotechnology
- Healthcare
- International Journal of Computational Biology and Drug Design
- International Journal of Molecular Sciences
- Journal of Liquid Chromatography & Related Technologies
- Jordan Journal of Pharmaceutical Sciences
- Journal of Molecular Graphics and Modelling
- Journal of Multidisciplinary Healthcare
- Medicinal Chemistry Research
- Mini-Reviews in Medicinal Chemistry
- Molecules
- Molecular Diversity
- Military Medical Research
- Pharmaceuticals
- PLOS One
- Research & Reviews: Journal of Pharmaceutical Quality Assurance
- Research on Chemical Intermediates
- SAR and QSAR in Environmental Research
- Scientific Reports
- Uttar Pradesh Journal of Zoology
- Vaccines

#### **14. Research proposal peer reviewer**

- The Jordanian Scientific Research Support Fund Organization (5 proposals).



- Umm Al-Qura University Deanship of Scientific Research, Saudi Arabia (4 proposals).

#### 15. Promotion material peer reviewer

- February 2022, Promotion committee member for reviewing and evaluating the academic research work of a candidate faculty as a requirement for promotion purpose from assistant to associate rank.

#### 16. Training workshops

- Modern Teaching Strategies, Al-Zaytoonah University Accreditation and Quality Assurance Office, February 14-16<sup>th</sup> 2017.
- Application of E-Learning and National Qualification Framework (NQF), Al-Zaytoonah University Accreditation and Quality Assurance Office, February 23-25<sup>th</sup> 2021.

#### 17. Patents

Al Hanbali, Othman; Al-Shukri, Salah; Al-Matubsi, Hisham; Bataineh, Yazan; Dardas, Abdel Khaleq; Bakkour, Youssef; Alozizi, Abdelelah; Qannan, Aiman; Kamil, Lana; AlQadi, Tariq; Saleh, Maysoon; **Sabbah, Dima A.** "Formulations for Baby Animals." **Patent number:** 2017203330. Issue Date: June 27<sup>th</sup> 2019.

#### 18. Publications

##### A. Articles:

1. Sunoqrot S., Aliyeh S., Abusulieh S., **Sabbah D.** Vitamin E TPGS-Poloxamer Nanoparticles Entrapping a Novel PI3K $\alpha$  Inhibitor Potentiate Its Activity against Breast Cancer Cell Lines. *Pharmaceutics*, **2022**, Accepted.
2. Abu Khalaf, R., Shayah H., **Sabbah, D. A.** Trifluoromethylated aryl sulfonamides as novel CETP inhibitors: Synthesis, induced fit docking, pharmacophore mapping and subsequent in vitro validation. *Med. Chem.* **2022**, Accepted.



3. Hajjo, R., **Sabbah, D. A.**, Al Bawab, A. Q. Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers. *Diagnostics*, **2022**, Accepted
4. Sweidan, K., Elfadel, H., **Sabbah, D. A.**, Bardaweel, S. K., Hajjo, R., Anjum, S., Sinoj, J., Nair, V. A., Abu-Gharbieh, E., El-Huneidi, W. Novel Derivatives of 4,6-Dihydroxy-2-Quinolone-3-Carboxamides as Potential PI3K $\alpha$ . *ChemistrySelect* **2022**, Accepted.
5. Hajjo, R., **Sabbah, D. A.**, Tropsha A. Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects. *Pathogens*, **2022**, Accepted.
6. Bardaweel, S. K., Aljanabi, R., **Sabbah, D. A.**, Sweidan, K. Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer. *Molecules* **2022**, 27(9), 2887.
7. Al-Zuheiri, A.M.K, Sweidan, K. Harb, M. K., Bardaweel, S. K., Sunjuk, M., **Sabbah, D. A.** Synthesis, characterization and biological screening of new *n*-substituted -7-chloro-4-hydroxy-2-quinolone -3-carboxamides as promising anticancer agents. *Heterocycles* **2022**, Accepted.
8. **Sabbah, D. A.**, Samarat, H.H., Al-Shalabi, E., Bardaweel, S. K., Hajjo, R., Sweidan, K., Abu Khalaf, R., Al-Zuheiri, A. M., Abushaikh, G. Design, Synthesis, and Biological Examination of *N*-Phenyl-6-fluoro-4-hydroxy-2-quinolone-3-carboxamides as Anticancer Agents. *ChemistrySelect* **2022**, 7, e202200662.
9. Abu Arqoub, D., Mahmoud, N. N., Zaza, R., Abu Dahab, R. Khalil, E. A., **Sabbah, D. A.** The In Vitro Immunomodulatory Effects of Gold Nanocomplex on THP-1-Derived Macrophages. *J. Immunol. Res.* **2022**, 2022, ID 6031776



10. Abu Khalaf, R., Alqazaqi, S., Aburezeq, M., **Sabbah D.**, Albadawi, G., Abu Sheikha, G. Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation. *Curr. Comput. Aided Drug Des.* **2022**, 18, 9-25.
11. Abu Khalaf, R., Awad, M., Al-Essa, L., Mefleh, S., **Sabbah, D.**, Al-Shalabi, E., Shabeeb, I. Discovery, synthesis and in combo studies of Schiff's bases as promising dipeptidyl peptidase-IV inhibitors. *Mol. Divers.* **2022**, 26, 1213-1225.
12. Abu Khalaf, R., Awad, M., Al-Qirim, T., **Sabbah D.** Synthesis and Molecular Modeling of Novel 3,5-Bis(trifluoromethyl)benzylamino Benzamides as Potential CETP Inhibitors. *Med. Chem.* **2022**, 18, 4, 417-426.
13. Hajjo, R., **Sabbah, D.A.**, Bardaweel, S. K., Tropsha, A. Shedding the Light on Post-vaccine Myocarditis and Pericarditis in COVID-19 and non-COVID-19 Vaccine Recipients. *Vaccines* **2021**, 9, 1186.
14. **Sabbah, D. A.**, Hajjo, R., Sweidan, K., Zhong, H. A. An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors. *Curr. Comput. Aided Drug Des.* **2021**, 17 (6), 817-830.
15. Aljanabi, R.; Alsous, L.; **Sabbah, D. A.**; Gul, H. I.; Gul, M.; Bardaweel, S. K. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development. *Molecules* **2021**, 26 (19), 6019.
16. **Sabbah, D. A.**, Hajjo, R., Bardaweel, S.K., Zhong, H. A. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020). *Expert Opin. Ther. Pat.* **2021**, 31, 10, 877-892.



17. Hajjo, R., **Sabbah, D. A.**, Bardaweel, S. K., Tropsha, A. Identification of Tumor-specific MRI Biomarkers Using Machine Learning (ML). *Diagnostics* **2021**, 11, 742.
18. Bader, A., Bkhaitan, M.M., Abdalla A.N., Abdallah, Q. M. A., Ali, H. I., **Sabbah, D. A.**, Albadawi, G., Abu Sheikha, G. Design and Synthesis of 4-O-Podophyllotoxin Sulfamate Derivatives as Potential Cytotoxic Agents. *Evid.-Based Complementary Altern. Med.* **2021**, ID 6672807.
19. **Sabbah, D. A.**, Hajjo, R., Bardaweel, S.K., Zhong, H. A. An Updated Review on *Betacoronavirus* Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery. *Curr. Top. Med. Chem.* **2021**, 21 (7), 571-596.
20. **Sabbah, D. A.**, Hajjo, R., Bardaweel, S.K., Zhong, H. A. An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors. *Curr. Top. Med. Chem.* **2021**, 21 (6), 442-460.
21. **Sabbah, D. A.**, Haroon R. A., Bardaweel, S.K., Hajjo, R., Sweidan, K. *N*-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents. *Molecules* **2021**, 26 (1), 73.
22. **Sabbah, D. A.**, Al-Azaideh, B. A., Talib, W. H., Hajjo, R., Sweidan, K. A., Al-Zuheiri, A. M., Abu Sheikha, G., Shraim, S. New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation. *Acta Pharm.* **2021**, 71 (4), 545-565.





23. Abu Khalaf, R., Al Warafi, E., **Sabbah D.** Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and *in vitro* biological Evaluation. *Acta Pharm.* **2021**, 71 (4), 631-643.
24. Bilginer, S., Bardaweel, S. K., **Sabbah, D. A.**, Gul, H. I. Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3K $\alpha$ ). *Anticancer Agents Med. Chem.* **2021**, 21 (6), 716-724.
25. Bardaweel, S.K., Hajjo, R., **Sabbah, D. A.** Sitagliptin: a potential drug for the treatment of COVID-19? *Acta Pharm.* **2021**, 71, 175-184.
26. Abu Khalaf, R., Abu Jarad, H., Al-Qirim, T., **Sabbah D.** Synthesis, Biological Evaluation, and QPLD Studies of Piperazine Derivatives as Potential DPP-IV Inhibitors. *Med. Chem.* **2021**, 17, 937-944.
27. **Sabbah, D. A.**, Hasan, S. E., Abu Khalaf, R., Bardaweel, S.K., Hajjo, R., Alqaisi, K. M., Sweidan, K. A., Al-Zuheiri, A. M. Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents. *Molecules* **2020**, 25 (22), 5348.
28. Hajjo, R., **Sabbah, D. A.**, Bardaweel, S.K. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19. *ACS Omega* **2020**, 5 (46), 29765-79.
29. Sunoqrot, S., Al-Shalabi, E., **Sabbah, D. A.**, Al-Majawleh, M., Abusara, O. H. Remote Teaching and Learning in a Pandemic: Reflections from Chemistry Instructors at a Pharmacy School in Jordan. *J. Chem. Educ.* **2020**, 97 (9), 3129-34.



30. Abu Khalaf, R., Masalha D., **Sabbah D.** DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design, and Synthesis. *Curr. Comput. Aided Drug Des.* **2020**, 16 (3), 295-307.
  
31. Mahmoud, N. N., Abu Arqoub, D., Zaza, R., **Sabbah, D. A.**, Khalil, E. A., Abu Dahab, R. Gold Nanocomplex Strongly Modulates the PI3K/AKT Pathway and Other Pathways in MCF-7 Breast Cancer Cell Line. *Int. J. Mol. Sci.* **2020**, 21 (9), 3320-3330.
  
32. **Sabbah, D. A.**, Hajjo, R., Sweidan, K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. *Curr. Top. Med. Chem.* **2020**, 20 (10), 815-834.
  
33. Mahmoud, N. N., **Sabbah, D. A.**, Abu Dahab, R. M., Abu Arqoub, D., Rashed M., Ibrahim, A. H., Khalil, E. A. Cholesterol-Coated Gold Nanorods as an Efficient Nano-Carrier for Chemotherapeutic Delivery and Potential Treatment of Breast Cancer: In Vitro Studies Using MCF-7 Cell Line. *RSC Adv.* **2019**, 9, 12718-12731.
  
34. Hamadneh, L.A., **Sabbah, D. A.**, Hikmat, S. J., Al-Samad, L., Hasan, M., Al-Qirim, T.M., Hamadneh, I. M., Al-Dujaili, A. H. Hypolipidemic effect of novel 2,5-bis(4-hydroxy benzylidenamino)-1,3,4-thiadiazole as potential peroxisome proliferation-activated receptor- $\alpha$  agonist in acute hyperlipidemic rat model. *Mol. Cell. Biochem.* **2019**; 458 (1-2): 39-47.
  
35. Islam, M. T., Biswas, S., Bagchi, R., Khan, R. Md., Khalipha, A.B.R., Rouf, R., Jamal Uddin, S., Shilpi. J. A., Bardaweel, S. K., **Sabbah, D. A.**, Mubarak, M. S. Ponocidin as a promising anticancer agent: Its biological and biopharmaceutical profile along with a molecular docking study. *Biotechnol. Appl. Biochem.* **2019**; 66(3): 434-444.



36. **Sabbah, D. A.**, Hasan Ibrahim, A., Talib, W. H., Alqaisi K. M., Sweidan, K., Bardaweel, S., Abu Sheikha, G., Zhong, H. A., Al-Shalabi E., Abu Khalaf, R., Mubarak, M.S. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents. *Med. Chem.* **2019**; 15 (4), 417-429.
37. Jasim, S. H., Abu Sheikha, G., Abuzaid, H. M., Al-Qirim, T.M., Shattat, G. F, **Sabbah, D. A.**, Ata, S.A., Aboumair, M. S., Sweidan, K., Bkhaitan, M. M. Synthesis and in vivo lipid-lowering activity of novel imidazole-5-carboxamide derivatives in Triton-WR-1339-induced hyperlipidemic Wistar rats. *Chem. Pharm. Bull.* **2018**; 66 (10), 953-958.
38. Al-Blewi, F.F., Rezki, N., Al-Sodies, S.A., Bardaweel, S.K., **Sabbah, D. A.**, Messali, M., Aouad M. R. Novel Amphiphilic Pyridinium Ionic Liquids-Supported Schiff Bases. Ultrasound Assisted Synthesis, Molecular Docking and Anticancer Evaluation. *Chem. Cent J.* **2018**; 12 (1), 118-36.
39. Sweidan, K., Zalloum, H., **Sabbah, D. A.**, Idris G., Abudosh, K., Mubarak, M.M. Synthesis, characterization, and anticancer evaluation of some new N1-(anthraquinon-2-yl) amidrazone derivatives. *Can. J. Chem.* **2018**, 96 (12), 1123-1128.
40. Khan, H., **Sabbah, D. A.**, Zafar, M., Mubarak, M.S. Molecular Modeling Studies of Coruscanone (A) Core Nucleus as Potential Antifungal Agents. *Life Sci.*, **2018**, 209, 332-340.
41. **Sabbah, D. A.**, Al-Tarawneh, F., Talib, W., Sweidan, K., Bardaweel, S., Al-Shalabi, E., Zhong, H.A., Abu Sheikha, G., Abu Khalaf, R., Mubarak, M.S. Benzoin Schiff Bases: Design, Synthesis, and Biological



- Evaluation as Potential Antitumor Agents. *Med. Chem.* **2018**, 14 (7), 695-708.
42. Al-Qtaitat, M. A., El-Abadelah, M. M., **Sabbah, D. A.**, Bardaweel, S., Sweidan, K., Sabri, S. S., Mubarak, M. S. Synthesis, characterization, and bioactivity of new bisamidrazone derivatives as possible anticancer agents. *Med. Chem. Res.* **2018**, 27, 1419-1431.
43. Abu Khalaf, R., **Sabbah D.**, Al-Shalabi E., Al-Sheikh, I., Albadawi G., Abu Sheikha G. Synthesis, Structural Characterization and Docking Studies of Sulfamoyl-Phenyl Acid Esters as DPP-IV Inhibitors. *Curr. Comput. Aided Drug Des.* **2018**, 14 (2), 142-151.
44. **Sabbah, D. A.**, Hishmah, B., Sweidan, K., Bardaweel, S., AlDamen, M., Zhong, H. A., Hasan Ibrahim, A., Abu Khalaf, R., Al-Qirim, T., Abu Sheikha, G., Mubarak, M.M. Structure-Based Drug Design: Synthesis, X-Ray Crystallography, and Biological Evaluation of *N*-substituted- 4-hydroxy-2-quinolone-3-carboxamides as Potential PI3K $\alpha$  Inhibitors. *Anticancer Agents Med. Chem.* **2018**, 18 (2), 263-276.
45. Sweidan K., Elayan M., **Sabbah D.**, Idrees G., Arafat T. Study of Forced Degradation Behavior of Amisulpride by LC-MS and NMR and Development of a Stability-Indicating Method. *Curr. Pharm. Anal.* **2018**, 14 (2), 157-165.
46. Abu Khalaf, R., **Sabbah D.**, Al-Shalabi E., Bishtawi S., Albadawi G., Abu Sheikha G. Synthesis, Biological Evaluation, and Molecular Modeling Study of Substituted Benzyl Benzamides as CETP Inhibitors. *Arch. Pharm.* **2017**, 350 (12), e1700204
47. **Sabbah, D. A.**, Sweidan, K. Molecular Docking Studies of Novel Thiosemicarbazone-Based Indoles as Potential PI3K $\alpha$  Inhibitors. *Lett. Drug Des. Discov.* **2017**, 14(11): 1252-1258.



48. Arabiyat S., Kasabri V., Al-Hiari Y., Bustanji Y.K., Albashiti R., Almasri I. M., **Sabbah D. A.** Antilipase and Antiproliferative Activities of Novel Fluoroquinolones and Triazolofluoroquinolones. *Chem. Biol. Drug Des.* **2017**, 90 (6), 1282–1294.
49. Sweidan, K., **Sabbah, D. A.**, Bardaweel, S., Abu Sheikha, G., Al-Qirim, T., Salih, H., El-Abadelah, M. M., Mubarak, M. S., Voelter, W. Facile Synthesis, Characterization and Cytotoxicity Study of New 3-(Indol-2-Yl) Bicyclotetrazatridecahexaens. *Can. J. Chem.* **2017**, 95(8): 858-862.
50. Abu Khalaf, R., Abd El-Aziz H., **Sabbah D.**, Albadawi G., Abu Sheikha G. CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping, and Synthesis. *Lett. Drug Des. Discov.* **2017**, 14 (12), 1391-1400.
51. Hikmat, S., Al-qirim T., Alkabbani, D., Shattat, G., Abu Sheikha, G., **Sabbah, D.**, Abu khalaf, R., Al-hiari, Y. Synthesis and in vivo anti-hyperlipidemic activity of novel N-benzoylphenyl-2-furamide derivatives in Wistar rats. *Trop. J. Pharm. Res.* **2017**, 16, 1, 193-201
52. Abu Khalaf, R., Al-Rawashdeh S., **Sabbah D.**, Abu Sheikha G. Molecular Docking and Pharmacophore Modeling Studies of Fluorinated Benzamides as Potential CETP Inhibitors. *Med. Chem.* **2017**, 13 (3), 239-253
53. **Sabbah, D. A.**, Zhong H. Modeling the Protonation States of  $\beta$ -Secretase Binding Pocket by Molecular Dynamics Simulations and Docking Studies. *J. Mol. Graph. Model.* **2016**, 68, 206-215
54. Sweidan K., **Sabbah D. A.**, Bardaweel S., Dush K. A., Sheikha G.A., Mohammad S. Mubarak. Computer-Aided Design, Synthesis, and Biological Evaluation of New Indole-2-Carboxamide Derivatives as



PI3K $\alpha$ /EGFR Inhibitors. *J. Bioorg. Med. Chem. Lett.* **2016**, 26, 2685-2690

55. **Sabbah D. A.**, Hu J., Jian Hu, Zhong H.A. Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors. *Curr. Top. Med. Chem.* **2016**, 16, 1-14.

56. **Sabbah D. A.**, Saada M., Abu Khalaf R., Bardaweel S., Sweidan K., Al-Qirim T., Al-Zughier A., Abdel Halim H., Abu Sheikha G. Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinositide 3-kinase (PI3K $\alpha$ ). *J. Bioorg. Med. Chem. Lett.* **2015**, 25, 3120-3124.

57. Abu Khalaf R., Jarekji Z., Al-Qirim T., **Sabbah D.**, Shattat G. Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors. *Can. J. Chem.* **2015**, 93, 721-929.

58. Sweidan K., **Sabbah D. A.**, Engelmann J., Abdel-Halim, H., Abu Sheikha G. Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3K $\alpha$  Inhibitors. *Lett. Drug Des. Discov.* **2015**, 12, 1-8.

59. Sweidan K., Engelmann J., Abu Rayyan W., **Sabbah D.**, Abu Zarga M., Al-Qirim T., Al-Hiari Y., Abu Sheikha G., Shattat G. Synthesis and Preliminary Biological Evaluation of New Heterocyclic Carboxamide Models. *Lett. Drug Des. Discov.* **2015**, 12, 417-429.

60. **Sabbah D.A.**, Vennerstrom J.L., Zhong H. Binding Selectivity Studies of Phosphoinositide 3-Kinases Using Free Energy Calculations. *J. Chem. Inf. Model.* **2012**, 52, 3213-3224.

61. **Sabbah D.A.**, Simms N.A., Dong, Y., Ezell, E.L., Brattain M.G., Vennerstrom J.L., Zhong H. *N*-phenyl-4-hydroxy-2-quinolone-3-





QFG11/0110 - 3.1E	Curriculum Vitae Form - Procedures of Appointment and Promotion Committee
-------------------	---

carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3K $\alpha$ ). *J. Bioorg. Med. Chem.* **2012**, 20, 7175-7183.

62. **Sabbah D.A.**, Simms N.A., Brattain M.G., Vennerstrom J.L., Zhong H. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. *J. Bioorg. Med. Chem. Lett.* **2012**, 22, 876-880.

63. **Sabbah D.A.**, Brattain M.G., Zhong H. Dual Inhibitors of PI3K/mTOR or MTOR-Selective Inhibitors: Which way Shall We Go? *Curr. Med. Chem.* **2011**, 18, 5528-5544.

64. **Sabbah D.A.**, Vennerstrom J.L., Zhong H. Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases. *J. Chem. Inf. Model.* **2010**, 50, 1887-1898.

65. **Book Chapter:**

Abu Khalaf, R. A., Alhusban, A. A., Al-Shalabi, E., Al-Sheikh, I., Sabbah, D. A.: **Isolation and structure elucidation of bioactive polyphenols**. In: *Studies in Natural Products Chemistry. Volume 63*, 1<sup>st</sup> edn. Elsevier; 2019: 267-337.